title: Sinonasal malignancies in children: a 10-year, single-institutional review.
abstract: OBJECTIVE
  Sinonasal malignancies in children are rare, histologically diverse tumors that present diagnostic and management challenges. The purpose of this study is to review the experience of a single cancer center in the management of pediatric sinonasal malignancies.
  
  
  METHODS
  Retrospective review.
  
  
  METHODS
  Retrospective chart review.
  
  
  RESULTS
  Forty-four patients were identified. The median age was 12 years (range: 2-17), 54% were female, and the maxillary sinus was the most common primary site. Facial swelling and pain were the most common presenting complaints. Thirty-four patients (76%) in this series had paranasal sinus sarcomas, three patients had esthesioneuroblastomas, and eight patients had carcinomas. The 5-year overall survival, disease-specific survival, and recurrence rate for the entire group was 71%, 81%, and 43%, respectively.
  
  
  CONCLUSIONS
  Pediatric sinonasal malignancies are rare, locally aggressive tumors associated with nonspecific signs and symptoms. Multimodality treatment can result in 5-year overall and disease-specific survival rates of over 70%. A multidisciplinary team approach is essential to optimize outcomes and limit the morbidity of treatment.
authors: Department of Head and Neck Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
authors: Jose P
authors: JP
authors: Zevallos
authors: Kunal S
authors: KS
authors: Jain
authors: Dianna
authors: D
authors: Roberts
authors: Adel
authors: A
authors: El-Naggar
authors: Ehab Y
authors: EY
authors: Hanna
authors: Michael E
authors: ME
authors: Kupferman
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local; D009669:Nose Neoplasms / Q000453:epidemiology* / Q000628:therapy*; D010255:Paranasal Sinus Neoplasms / Q000453:epidemiology* / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate